Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Am J Kidney Dis. 2022 Apr 8;80(5):610–618.e1. doi: 10.1053/j.ajkd.2022.02.021

Table 1.

Baseline characteristics of 2,720 eligible CRIC participants overall and by self-reported race.

Characteristic Overall (N=2720) White (N=1454) Black (N=1266) P-values
Age, year, mean (SD) 65.4 (9.3) 66.0 (9.5) 64.7 (9.1) <0.001
Women, n (%) 1204 (44) 554 (38) 650 (51) <0.001
Hispanic ethnicity, n (%) 116 (4.3) 104 (7.2) 12 (0.9) <0.001
High school graduate, n (%) 2378 (88) 1362 (94) 1016 (80) <0.001
Have health insurance, n (%) 2588 (95) 1392 (96) 1196 (95) 0.1
Current cigarette smokers, n (%) 263 (10) 82 (6) 181 (14) <0.001
Medical history, n (%)
 Cardiovascular disease 993 (37) 518 (36) 475 (38) 0.3
 Heart failure 267 (10) 129 (9) 138 (11) 0.08
 Diabetes mellitus 1439 (53) 702 (48) 737 (58) <0.001
 Dyslipidemia 2226 (82) 1214 (84) 1012 (80) 0.02
 Receipt of ACE-I or ARB 1758 (65) 919 (64) 839 (67) 0.07
 Receipt of any antihypertensive medication 2424 (89) 1236 (85) 1188 (94) <0.001
Baseline laboratory values and vital signs
 Estimated glomerular filtration rate, mL/min/1.73m2, mean (SD) 51 (17) 52 (16) 52 (17) 0.7
 Urine-Protein-to-Creatine Ratio, g/g, median (IQR) 0.2 (0.0–0.4) 0.2 (0.0–0.4) 0.2 (0.0–0.6) <0.001
 Body mass index, kg/m2, mean (SD) 32 (7) 31 (7) 34 (7) <0.001
 Systolic blood pressure, mmHg, mean (SD) 126 (19) 122 (17) 130 (20) <0.001
 Diastolic blood pressure, mmHg, mean (SD) 69 (12) 67 (11) 71 (12) <0.001

ACE-I; Angiotensin-converting enzyme inhibitor, ARB; Angiotensin-receptor blockers,